System analysis based on the migration- and invasion-related gene sets identifies the infiltration-related genes of glioma

The current database has no information on the infiltration of glioma samples. Here, we assessed the glioma samples’ infiltration in The Cancer Gene Atlas (TCGA) through the single-sample Gene Set Enrichment Analysis (ssGSEA) with migration and invasion gene sets. The Weighted Gene Co-expression Network Analysis (WGCNA) and the differentially expressed genes (DEGs) were used to identify the genes most associated with infiltration. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the major biological processes and pathways. Protein–protein interaction (PPI) network analysis and the least absolute shrinkage and selection operator (LASSO) were used to screen the key genes. Furthermore, the nomograms and receiver operating characteristic (ROC) curve were used to evaluate the prognostic and predictive accuracy of this clinical model in patients in TCGA and the Chinese Glioma Genome Atlas (CGGA). The results showed that turquoise was selected as the hub module, and with the intersection of DEGs, we screened 104 common genes. Through LASSO regression, TIMP1, EMP3, IGFBP2, and the other nine genes were screened mostly in correlation with infiltration and prognosis. EMP3 was selected to be verified in vitro. These findings could help researchers better understand the infiltration of gliomas and provide novel therapeutic targets for the treatment of gliomas.

[1]  Zhicheng Hu,et al.  Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells , 2022, MedComm.

[2]  Lai-Feng Wei,et al.  Prognostic value of IGFBP2 in various cancers: a systematic review and meta‐analysis , 2022, Cancer medicine.

[3]  Ximing Xu,et al.  The oncogenic role of tubulin alpha-1c chain in human tumours , 2022, BMC Cancer.

[4]  R. Dempsey,et al.  Enhanced expression of pentraxin-3 in glioblastoma cells correlates with increased invasion and IL8-VEGF signaling axis , 2021, Brain Research.

[5]  M. Morcillo,et al.  Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography , 2021, Cancers.

[6]  Jing Yang,et al.  Tumor metastasis: Mechanistic insights and therapeutic interventions , 2021, MedComm.

[7]  F. Che,et al.  RAB42 Promotes Glioma Pathogenesis via the VEGF Signaling Pathway , 2021, Frontiers in Oncology.

[8]  X. Xiong,et al.  TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment , 2021, Frontiers in Genetics.

[9]  Wei Wang,et al.  EMP3 negatively modulates breast cancer cell DNA replication, DNA damage repair, and stem-like properties , 2021, Cell Death & Disease.

[10]  Zhicheng Hu,et al.  The prognostic factors and nomogram for patients with high-grade gliomas , 2021, Fundamental Research.

[11]  Qianghu Wang,et al.  Chitinase-3-like-1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. , 2021, The Journal of clinical investigation.

[12]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[13]  Qun Chen,et al.  EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion , 2021, Journal of Experimental & Clinical Cancer Research.

[14]  Qun Chen,et al.  EMP3 mediates glioblastoma‐associated macrophage infiltration to drive T cell exclusion , 2021, Journal of Experimental & Clinical Cancer Research.

[15]  B. Pang,et al.  Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients , 2021, PeerJ.

[16]  P. Schirmacher,et al.  Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria , 2020, Cell Death & Disease.

[17]  Xiaoren Zhang,et al.  Chitinase-3 like-protein-1 function and its role in diseases , 2020, Signal Transduction and Targeted Therapy.

[18]  B. Kristensen,et al.  Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas. , 2020, Journal of neuropathology and experimental neurology.

[19]  Yuxin Guo,et al.  Strategies for visualizing inflammation , 2020 .

[20]  A. Seltsam,et al.  Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype , 2020, Nature Communications.

[21]  A. Órfão,et al.  Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications , 2020, Scientific Reports.

[22]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[23]  John H. Zhang,et al.  The potential of Slit2 as a therapeutic target for central nervous system disorders , 2020, Expert opinion on therapeutic targets.

[24]  M. Fukuda,et al.  Rab7B/42 Is Functionally Involved in Protein Degradation on Melanosomes in Keratinocytes , 2020, Cell structure and function.

[25]  Frank Lindseth,et al.  3D ultrasound-guided resection of low-grade gliomas: principles and clinical examples. , 2019, Neurosurgical focus.

[26]  Seung-Hoon Lee,et al.  Nogo receptor–vimentin interaction: a novel mechanism for the invasive activity of glioblastoma multiforme , 2019, Experimental & Molecular Medicine.

[27]  Yi-Shan Chen,et al.  In-depth mining of clinical data: the construction of clinical prediction model with R. , 2019, Annals of translational medicine.

[28]  Qiuyue Zhong,et al.  Seven genes for the prognostic prediction in patients with glioma , 2019, Clinical and Translational Oncology.

[29]  Wei Liu,et al.  CancerSEA: a cancer single-cell state atlas , 2018, Nucleic Acids Res..

[30]  Yubo Wang,et al.  Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme , 2018, Journal of experimental & clinical cancer research : CR.

[31]  Yuan-yuan Qin,et al.  SPOCD1 promotes the proliferation and metastasis of glioma cells by up-regulating PTX3. , 2018, American journal of cancer research.

[32]  Meng Chen,et al.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples , 2018, Oncoimmunology.

[33]  Christos Davatzikos,et al.  Multi-stage Association Analysis of Glioblastoma Gene Expressions with Texture and Spatial Patterns , 2018, BrainLes@MICCAI.

[34]  Chia-Feng Lu,et al.  Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro , 2017, Journal of Nanobiotechnology.

[35]  Soonmee Cha,et al.  Current Clinical Brain Tumor Imaging , 2017, Neurosurgery.

[36]  G. Sauter,et al.  Deletion of 8p is an independent prognostic parameter in prostate cancer , 2016, Oncotarget.

[37]  L. Girard,et al.  SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas , 2016, EBioMedicine.

[38]  J. R. Plaça,et al.  HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma , 2016, Tumor Biology.

[39]  Shun-Fa Yang,et al.  Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo , 2016, Journal of Neuro-Oncology.

[40]  A. Sablina,et al.  Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism. , 2016, Cancer cell.

[41]  Jinglong Wang,et al.  Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer , 2016, Molecular Cancer.

[42]  D. Friedmann-Morvinski,et al.  Targeting NF-κB in glioblastoma: A therapeutic approach , 2016, Science Advances.

[43]  G. Sauter,et al.  8p deletion is strongly linked to poor prognosis in breast cancer , 2015, Cancer biology & therapy.

[44]  Toshihiko Wakabayashi,et al.  Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy , 2014, BioMed research international.

[45]  A. Wu,et al.  Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway , 2014, British Journal of Cancer.

[46]  Shuang Huang,et al.  SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. , 2014, Neoplasia.

[47]  P. Wen,et al.  Current status of antiangiogenic therapies for glioblastomas , 2014, Expert opinion on investigational drugs.

[48]  C. Garlanda,et al.  The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas , 2013, Journal of Neuroimmunology.

[49]  Guang-shun Yang,et al.  Elevated SHOX2 Expression is Associated with Tumor Recurrence of Hepatocellular Carcinoma , 2013, Annals of Surgical Oncology.

[50]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[51]  Stephanie Roessler,et al.  Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. , 2012, Gastroenterology.

[52]  D. Dietrich,et al.  SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[53]  H. Nielsen,et al.  Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. , 2010, European journal of cancer.

[54]  Harish Srinivasan,et al.  Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[55]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[56]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[57]  N. Brünner,et al.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival , 2009, Journal of Neuro-Oncology.

[58]  T. Yoshikawa,et al.  Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer , 2009, Gastric Cancer.

[59]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[60]  J. Piontek,et al.  Structure and function of claudins. , 2008, Biochimica et biophysica acta.

[61]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 promotes glioma development and progression , 2007, Proceedings of the National Academy of Sciences.

[62]  T. Ushijima,et al.  Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers. , 2007, Life sciences.

[63]  B. Jensen,et al.  Is YKL-40 a new therapeutic target in cancer? , 2007, Expert opinion on therapeutic targets.

[64]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Miguel Alaminos,et al.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.

[66]  C. Garlanda,et al.  Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. , 2005, Annual review of immunology.

[67]  N. Brünner,et al.  Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer , 2004, Clinical Cancer Research.

[68]  D. Denhardt,et al.  Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase , 2004, British Journal of Cancer.

[69]  Xu-wen Liu,et al.  Tissue Inhibitor of Metalloproteinase-1 Protects Human Breast Epithelial Cells Against Intrinsic Apoptotic Cell Death via the Focal Adhesion Kinase/Phosphatidylinositol 3-Kinase and MAPK Signaling Pathway* , 2003, Journal of Biological Chemistry.

[70]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[71]  D. Gomez,et al.  Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .